• Medyssey received FDA 510(k) clearance on Oct. 15, 2026, for its Odys-SI Screw sacroiliac joint fusion implant.
• The clearance expands its US spinal implant portfolio into sacroiliac joint fusion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medyssey Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261016600742), on October 16, 2026, and is solely responsible for the information contained therein.